Forte Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul A. Wagner
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3060 Pegasus Park Drive Dallas TX United States of America 75247
- IPO Date
- Apr 13, 2017
- CIK
- 0001419041
- Website
- fortebiorx.com
- Similar Companies
- Business
- Forte Biosciences, Inc. (FBRX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and autoimmune-related diseases, including celiac disease, vitiligo, alopecia areata and graft-versus-host disease. The company's lead product candidate is FB-102, a proprietary anti-CD122 monoclonal antibody that targets key pathways in IL-2/IL-15 receptors to modulate NK cells and certain T cell subsets; FB-102 is advancing in multiple clinical programs, including a Phase 2 trial in celiac disease with topline data expected in 2026, a vitiligo trial with enrollment commenced and topline data anticipated in the first half of 2026, and an alopecia areata trial initiating in the second half of 2025 with topline data expected in 2026. In June 2025, Forte announced positive data from an FB-102 celiac disease study; in November 2024, the company completed an oversubscribed $53 million private placement financing from leading healthcare institutional investors including OrbiMed, Janus Henderson Investors and BVF Partners LP to advance FB-102 programs; and in November 2025, Forte issued inducement grants under Nasdaq listing rules and reported $93.4 million in cash and cash equivalents as of Q3 2025. Founded in 2017 and headquartered at 3060 Pegasus Park Drive, Building 6, Dallas, Texas, Forte operates in the United States within the biotechnology sector, targeting unmet needs in dermatological and inflammatory conditions with no subsidiaries or parent company relationships disclosed.
Company News
argenx Completes Acquisition of Forte Biosciences, Inc.
Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--FBRX, LXFR, SMTI, and MKTX
Are FBRX, LXFR, HUN, OLN Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX
Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX)
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
Dow Jones still green but Nasdaq slips to start 'massive week' as oil tumbles
FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders